<DOC>
	<DOCNO>NCT01481870</DOCNO>
	<brief_summary>The clinical benefit sunitinib sorafenib demonstrated patient cytokine-refractory metastatic renal cell carcinoma . Sunitinib also show improve progression free survival overall survival comparative study interferon-alpha . When sunitinib use first-line molecular-targeted therapy , switch sorafenib one treatment option disease progression . Reversely , sorafenib use first-line molecular-targeted therapy , sunitinib use second-line therapy . The goal cancer treatment cure , cure possible , prolong survival . In study , sunitinib sorafenib administer first-line molecular-targeted therapy treatment switch test drug , sorafenib sunitinib , disease progression detect assess treatment sequence produce long progression free survival offer well safety profile ( cause few adverse event ) . The purpose trial compare progression free survival first line sunitinib versus sorafenib , two treatment sequence , i.e . sunitinib follow sorafenib versus sorafenib follow sunitinib .</brief_summary>
	<brief_title>Comparison Sequential Therapies With Sunitinib Sorafenib Advanced Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Age : 2080 year old , inclusive ECOG performance status 0 , 1 , 2 MSKCC risk favorable intermediate Histologically confirm renal cell carcinoma No ischemic heart disease Laboratory find meet follow criterion : 1 . Respiratory function : % VC , 80 % FEV1.0,70 % 2 . Hematology : white blood cell count4,000/mm3 , platelet count100,000/mm3 3 . Clinical chemistry : GOT GPT within normal range medical institution ; total bilirubin &lt; 1.5 x ULN 4 . Serum creatinin &lt; 2.0mg/dl , blood urea nitrogen ( BUN ) &lt; 25mg/dl 5 . Echocardiographic estimation leave ventricular ejection fraction high low limit reference range medical institution . History malignancy Central nervous system metastasis . However , patient remain asymptomatic , new enlarge lesion CNS within 6 month enrollment study , require corticosteroid may enrol . History cardiac infarction , unstable angina , congestive heart failure , symptomatic peripheral vascular disease within 12 month enrollment History cerebrovascular disorder include transient ischemic attack ( TIA ) Pregnancy possible pregnancy time study Ongoing grade 2 adverse event prior treatment Prior treatment anticancer therapy include cytokine therapy interferonalpha interleukin2 Prior treatment mTOR inhibitor Prior treatment sunitinib sorafenib Treatment test drug clinical research within 4 week enrollment study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>renal cell carcinoma</keyword>
	<keyword>sorafenib</keyword>
	<keyword>sunitinib</keyword>
	<keyword>crossover</keyword>
</DOC>